[September 02, 2014]

Agilent Technologies Introduces Next-Generation Sequencing Cancer Research Panels

Agilent Technologies (News - Alert) Inc. (NYSE: A) today introduced ClearSeq AML, the first product in the ClearSeq line of next-generation cancer research panels, which targets 48 selected exons in 20 of the most commonly mutated genes found in acute myeloid leukemia.

Designed in collaboration with Dr. Robert Ohgami and Dr. Daniel Arber at the Stanford Department of Pathology, Stanford University, ClearSeq AML provides comprehensive coverage of mutations and enables swift progression of sample processing to analysis in less than 48 hours. The AML gene panel will be followed by the release of additional ClearSeq panels for cancer research throughout the coming months.

"We are pleased to introduce the ClearSeq family of products, a comprehensive set of targeted NGS gene panels for cancer research," said Jacob Thaysen, vice president and general manager of Agilent's Diagnostics and Genomics Group. "ClearSeq NGS panels are expert-identified products that will provide customers with a complete end-to-end anatomical-to-molecular genomics portfolio that includes solutions ranging from IHC for cancer diagnosis to NGS for cancer research."

Acute myeloid leukemia (AML) is the most common myeloid neoplasm affecting adults, and the role of chromosomal structural variations in its molecular pathogenesis is well documented. In recent years, next-generation sequencing has led to a revolution in the study of hematological malignancies and shown that insertions, deletions (indels) and mutations play an essential part in the pathogenesis of AML. Genetic information coupled with stadard anatomical findings has provided a deeper characterization and classification of AML.

ClearSeq AML provides 99.9 percent design coverage of targeted coding exons. Agilent's high-performance cancer panels enable the study of more complex genomic alterations in cancer, and deliver quick and accurate identification of relevant information. ClearSeq panels are based on SureSelect and HaloPlex technology, offering superior sensitivity and accuracy compared with other hybridization or PCR (News - Alert)-based methods, thus minimizing the risk of false-positive results. ClearSeq panels can be easily incorporated into routine laboratory workflows. Sequence data analysis and mutation reporting can be completed in three simple steps using Agilent's SureCall software.

To learn more about how to incorporate this powerful set of panels into your research protocol, visit www.agilent.com/genomics/ClearSeqAML.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com.

In September 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. On Aug. 1, 2014, the company's electronic measurement business began operating as Keysight Technologies, Inc., a wholly owned subsidiary. The separation is expected to be completed in early November 2014.

Forward-Looking Statements

This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding the separation of Agilent's electronic measurement business; future revenues, earnings and profitability; the future demand for the company's products and services; and customer expectations. These forward-looking statements involve risks and uncertainties that could cause Agilent's results to differ materially from management's current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of our customers' businesses; unforeseen changes in the demand for current and new products, technologies, and services; customer purchasing decisions and timing, and the risk that we are not able to realize the savings expected from integration and restructuring activities.

In addition, other risks that Agilent faces include those detailed in Agilent's filings with the Securities and Exchange Commission, including our latest Form 10-K and Form 10-Q. Forward-looking statements are based on the beliefs and assumptions of Agilent's management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.

In addition, other risks that Agilent faces include those detailed in Agilent's filings with the Securities and Exchange Commission, including our latest Form 10-K and Form 10-Q. Forward-looking statements are based on the beliefs and assumptions of Agilent's management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.

[ Back To TMCnet.com's Homepage ]